The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease

Behav Brain Res. 2009 Nov 5;203(2):304-7. doi: 10.1016/j.bbr.2009.04.035. Epub 2009 May 3.

Abstract

Acute injections of 8mg/kg of 3,4-dihydroxy-l-phenylalanine (l-DOPA) or 0.05mg/kg rimonabant equally improved contralateral forepaw stepping in rats with unilateral 6-hydroxydopamine (6-OHDA) lesions, and their combination improved stepping more than either drug alone. However, 0.05mg/kg rimonabant did not alter the changes in stepping produced by acute injections of a dyskinesic dose of 35mg/kg l-DOPA. Thus, not only is a cannabinoid antagonist monotherapeutic in this animal model of Parkinson's disease, but it also enhances the therapeutic effect of a moderate, but not a high, dose of l-DOPA.

MeSH terms

  • Animals
  • Corpus Striatum / physiopathology
  • Disease Models, Animal
  • Hypokinesia / drug therapy
  • Levodopa / administration & dosage
  • Levodopa / therapeutic use
  • Male
  • Motor Activity
  • Oxidopamine / toxicity
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Piperidines / administration & dosage
  • Piperidines / therapeutic use*
  • Pyrazoles / administration & dosage
  • Pyrazoles / therapeutic use*
  • Rats
  • Rats, Long-Evans
  • Receptor, Cannabinoid, CB1 / antagonists & inhibitors*
  • Rimonabant

Substances

  • Piperidines
  • Pyrazoles
  • Receptor, Cannabinoid, CB1
  • Levodopa
  • Oxidopamine
  • Rimonabant